Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 23, 2017
Pharmacy Choice - Pharmaceutical News - Dr. Bastian Dehmel Appointed CMO of OxThera - October 23, 2017

Pharmacy News Article

 10/13/17 - Dr. Bastian Dehmel Appointed CMO of OxThera

STOCKHOLM, October 13, 2017 /PRNewswire/

OxThera AB, a Stockholm-based privately-held biopharmaceuticalcompanytodayannounced the appointment ofDr. Bastian Dehmelas their newChief Medical Officer.

OxThera is developing a novel treatment, Oxabact, for Primary Hyperoxaluria (PH), a severe and often fatal disease in children, and where there are currently no available therapies. The company is poised to initiate a pivotal Phase III study in PH with Oxabact in order to stop and/or delay disease progression.

"It is my pleasure to welcome Bastian as CMO of OxThera," said Matthew Gantz, CEO of OxThera."His extensive experience in the renal space and successful track record of drug development in both the US and Europe will enable OxThera to rapidly progress the development of Oxabact for treating Primary Hyperoxaluria."

"I am excited to join OxThera at this important juncture as we launch into the Oxabact Phase III pivotal study for patients with PH," said Dr. Dehmel. "This is a devastating disease for patients and their families and I truly hope that we can make a real difference. I am excited to work with Matthew and the entire OxThera team to deliver on the promise of this new therapy."

Dr. Dehmel joins OxThera after serving as Executive Medical Director and Global Development Leader for Amgen's calcimimetic franchise. He has extensive experience in the life science sector, having led Medical Affairs and Clinical Development teams responsible for drugs in Diabetes and End Stage Renal Disease. Bastian brings extensive experience in working with global regulatory agencies and was responsible for FDA and EMA approval of etelcalcetide, and more recently for the orphan pediatric drug approval of cinacalcet by EMA.

Oxabactis an oral product, composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), designed for enteric elimination of plasma oxalate. A complete clinical development plan for Oxabact has been presented in Protocol Assistance and End-of-Phase II meetings with EMA and FDA respectively.

PH is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If left untreated, the disease can cause kidney failure and premature death. Currently, the sole available cure is a combined transplantation of liver and kidneys.

Oxabact holds orphan drug designations in the EU and the US for the treatment of PH, and in EU for treatment of Short Bowel Syndrome (SBS).

About OxThera

OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluriafor two products;Oxabactand Oxazyme.


Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 23: Vitamin D Primer for Pharmacy Professionals
Last Chance
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement